idea-012 · vet · US
For subcutaneous placement by a licensed veterinarian or veterinary technician; in dogs and cats with diagnosed diabetes mellitus, to provide continuous interstitial; glucose readings for insulin-dose titration and hypoglycemia detection in the clinic and at; the owner's home, as an alternative to serial blood-glucose-curve sampling by repeated; venipuncture or lancet stick.
Back in research. The gate sent it there with 7 of 9 factors verified; nothing for you to decide yet. No department has been asked. 1 of 31 claims verified, 1 refuted. Nobody has yet written down what it rests on.
Subcutaneously-inserted enzymatic (glucose oxidase, amperometric) filament-type continuous glucose sensor, re-engineered from the decades-old glucose-oxidase amperometric sensing chemistry underlying first-generation human CGM products, in an adhesive/wrap form factor designed for haired skin (clipped-site or fur-parting adhesive rather than a human-skin patch), paired with a handheld or app-based reader, and a species-specific calibration algorithm accounting for feline/canine interstitial glucose kinetics and hematocrit ranges that differ from the human ranges the underlying sensing chemistry was originally calibrated against
In the mechanism, as the candidate file states it — the plain-language paragraph in ## Wrap has not been written yet. Domain: veterinary-diabetes-glucose-monitoring
No business case yet, so nothing here says who writes the cheque. /business-case idea-012 builds one.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-012 replaces this list with the real one.
Why it scored what it did: claim 1verified (21 CFR (Title 21 of the Code of Federal Regulations) 807.65(b) veterinary establishment-registration exemption); intended_use: is veterinary-only, which is what keeps this device outside FDA (US Food and Drug Administration) premarket review entirely per the frontmatter device_class: reasoning
What would settle it: Full-text check of CFR 807.65(b), 807.20(a), and 814.1(a) against this device's intended-use statement — a free eCFR lookup.
Why it scored what it did: claim 10unconfirmed (no CPT (Current Procedural Terminology)/HCPCS or federal payer code applies to a veterinary-only device; reimbursement, if any, runs through pet insurance, not established here)
What would settle it: Trupanion, Nationwide, and ASPCA pet-insurance policy documents for a CGM-coverage precedent — free to pull, just analyst review time.
Why it scored what it did: Claims 7, 8, 9 (no diagnosed diabetic dog/cat population figure sourced; no per-unit price sourced; no addressable-share figure sourced; owner/clinician willingness-to-pay stated explicitly as an unverifiable assumption, not a fact)
What would settle it: (a) a vet-epidemiology study or Banfield/BluePearl State of Pet Health report; (b) Abbott/Dexcom cash-pay pricing; (c) a licensed veterinary CGM adoption/market report — free to a few thousand dollars each.
Why it scored what it did: Claims 5, 6 (foundational glucose-oxidase amperometric chemistry traces to 1960s research, plausibly off-patent on age alone, but no patent search performed and newer Abbott/Dexcom/Medtronic process- or membrane-chemistry patents not…the rest of this reasoning
checked)
What would settle it: A formal Abbott/Dexcom/Medtronic patent search via USPTO (United States Patent and Trademark Office)/Google Patents/PatFT — a few hours of analyst time, free to low-cost.
Why it scored what it did: claim 5unconfirmed (indirect) — the underlying sensing chemistry is decades-old and publicly known, which suggests weak inherent defensibility against a fast-follower once the device ships
What would settle it: A competitive IP (intellectual property)/trademark/trade-dress scan of Abbott, Dexcom, Zoetis, and Heska veterinary-CGM activity — a few hours of desk research, low-to-no cost.
Why it scored what it did: Claims 3, 4 (published veterinary studies testing off-label FreeStyle Libre accuracy in diabetic cats/dogs; reliable at normal/high glucose, more variable at low glucose)
What would settle it: Primary-source read of the cited FreeStyle Libre 3 feline study and the ScienceDirect canine/feline CGM study — free via PubMed, about an hour.
Why it scored what it did: claim 1verified (indirect) — no FDA premarket review requirement for a veterinary-only device implies materially lower regulatory cost/timeline than a human CGM, though no claim in this file gives an actual cost or calendar estimate
What would settle it: A build cost/timeline model from contract-manufacturer quotes and comparable veterinary device launches — a human-attached estimate, no fixed cost.
Why it scored what it did: none — no claim in this file addresses existing veterinary CGM competitors, recent funding, launches, or recalls in this space
What would settle it: A market scan for existing veterinary CGM competitors, funding, launches, and recalls — free desk research, a few hours.
Why it scored what it did: none — no claim in this file addresses fit against current portfolio
What would settle it: Not connector-checkable — a human/strategic portfolio-fit judgment call for Tier 3, free but requires a human decision.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-012 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
1 claim(s) the Verifier found to be false — a refuted claim is a finding, and the loop owes each one an answer.
No cheapest next test written yet — /wrap idea-012 names one.
Nothing is waiting on a decision. The next move above is work, not a choice.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
unconfirmed (literature/recall connectors are Stage 0
ScanResult tools that structurally cannot carry a confidence tag), so factors-verified
and the composite are unchanged from the pre-research gate-check. Originally recommended
/research idea-012 next, targeting: TAM
(diagnosed diabetic dog/cat population, per-unit cash pricing, addressable share),
pet-insurance reimbursement precedent, primary-source reads of the off-label FreeStyle
Libre veterinary literature (claims 3-4), and FTO (a real patent search on
glucose-oxidase sensing, membrane chemistry, and manufacturing-process patents once a
patent-search tool/key is available). Re-confirmed again 2026-08-26 after a second
research round (claims 24-25) targeted Reimbursement and TAM specifically. Result
unchanged: still queued-research, 1/9 factors verified. Reimbursement: a genuine, thorough
search for a citable pet-insurance coverage source (NAPHIA industry data, PubMed,
veterinary-economics literature) found nothing usable — one real primary paper was located
and read in full but covers the wrong jurisdiction (Austria/Denmark/UK) and never mentions
diagnostic/monitoring devices; this is a genuine negative result, not an unsearched gap.
TAM: two new non-US prevalence comparators (UK VetCompass, Japan insurance-claims data)
added but both stay unconfirmed as literature findings; no post-1999 US-specific
prevalence estimate could be found despite a broadened search. Recommend: this candidate
has now had two research rounds without moving off 1/9; the remaining gaps (a US-specific
prevalence estimate, pet-insurance device-coverage data, FTO) look more like genuine data
scarcity or procurement gaps (PATENTSVIEW_API_KEY) than things a third research pass on
the same questions would resolve.
To finish it:
## Wrap section with a **Cheapest next test:** lineNo human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-012 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-012 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThis candidate has no ## Wrap section yet. Run /wrap idea-012 to write one.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 4 | claim 1verified (21 CFR 807.65(b) veterinary establishment-registration exemption); intended_use: is veterinary-only, which is what keeps this device outside FDA premarket review entirely per the frontmatter device_class: reasoning | Full-text check of CFR 807.65(b), 807.20(a), and 814.1(a) against this device's intended-use statement — a free eCFR lookup. |
| Reimbursement pathway | 1 | claim 10unconfirmed (no CPT/HCPCS or federal payer code applies to a veterinary-only device; reimbursement, if any, runs through pet insurance, not established here) | Trupanion, Nationwide, and ASPCA pet-insurance policy documents for a CGM-coverage precedent — free to pull, just analyst review time. |
| TAM | 1 | Claims 7, 8, 9 (no diagnosed diabetic dog/cat population figure sourced; no per-unit price sourced; no addressable-share figure sourced; owner/clinician willingness-to-pay stated explicitly as an unverifiable assumption, not a fact) | (a) a vet-epidemiology study or Banfield/BluePearl State of Pet Health report; (b) Abbott/Dexcom cash-pay pricing; (c) a licensed veterinary CGM adoption/market report — free to a few thousand dollars each. |
| FTO / IP | 2 | Claims 5, 6 (foundational glucose-oxidase amperometric chemistry traces to 1960s research, plausibly off-patent on age alone, but no patent search performed and newer Abbott/Dexcom/Medtronic process- or membrane-chemistry patents not…the rest of this reasoningchecked) | A formal Abbott/Dexcom/Medtronic patent search via USPTO/Google Patents/PatFT — a few hours of analyst time, free to low-cost. |
| Moat / defensibility | 1 | claim 5unconfirmed (indirect) — the underlying sensing chemistry is decades-old and publicly known, which suggests weak inherent defensibility against a fast-follower once the device ships | A competitive IP/trademark/trade-dress scan of Abbott, Dexcom, Zoetis, and Heska veterinary-CGM activity — a few hours of desk research, low-to-no cost. |
| Mechanism & clinical risk | 3 | Claims 3, 4 (published veterinary studies testing off-label FreeStyle Libre accuracy in diabetic cats/dogs; reliable at normal/high glucose, more variable at low glucose) | Primary-source read of the cited FreeStyle Libre 3 feline study and the ScienceDirect canine/feline CGM study — free via PubMed, about an hour. |
| Capital intensity & time-to-revenue | 3 | claim 1verified (indirect) — no FDA premarket review requirement for a veterinary-only device implies materially lower regulatory cost/timeline than a human CGM, though no claim in this file gives an actual cost or calendar estimate | A build cost/timeline model from contract-manufacturer quotes and comparable veterinary device launches — a human-attached estimate, no fixed cost. |
| Competitive intensity | — | none — no claim in this file addresses existing veterinary CGM competitors, recent funding, launches, or recalls in this space | A market scan for existing veterinary CGM competitors, funding, launches, and recalls — free desk research, a few hours. |
| Strategic fit & portfolio balance | — | none — no claim in this file addresses fit against current portfolio | Not connector-checkable — a human/strategic portfolio-fit judgment call for Tier 3, free but requires a human decision. |
To finish this packet:
## Wrap section with a **Cheapest next test:** lineSource file: knowledge-base/candidates/idea-012.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md